08 November, 2022
Crescom’s artificial intelligence solution for diagnosing ankylosing spondylitis, published in international journals for the first time in the world

(Date: July 27, 2022)


Crescom Co., Ltd. (CEO Jae Joon Lee), specialized in artificial intelligence medical image analysis solution development company, announced on 27th that it succeeded in developing an artificial intelligence ankylosing spondylitis diagnosis deep learning model and was published in “Therapeutic Advances in Musculoskeletal Disease” of a renowned international academic journal in the field of musculoskeletal health. In this paper, Professor Bonsan Koo of Seoul Paik Hospital participated as the first author, and Professor Taehwan Kim and Professor Seunghun Lee of Hanyang University and Professor Changho Kang of Anam Hospital of Korea University and others participated as co-authors.


Ankylosing spondylitis is an inflammatory disease, one of chronic spinal joint disease in which all joints between the vertebrae solidify into one, and if left unattended, it is a serious disease in which the spine cannot move due to fusion, which may interfere with daily life.


In this study, we developed an AI solution for grading mSASSS severity with detection of each corner of the cervical spine and lumbar vertebrae, which is the severity grade of ankylosing spondylitis. The average accuracy, sensitivity, and specificity of the vertebral edge mSASSS score were 91.6%, 80.3%, and 94.2%, respectively. This artificial intelligence solution is highly evaluated as it was developed for the first time in the world to classify the severity of ankylosing spondylitis with high accuracy and was first published in a renowned international journal.


Jae Joon Lee, CEO of Crescom, who developed the deep learning model, said, “We hope that through the artificial intelligence deep learning model developed this time, it is expected that it will help specialists and contribute to more convenient and accurate early diagnosis of ankylosing spondylitis and accurate evaluation of the progress and treatment effect.”


Meanwhile, the international journal “Therapeutic Advances in Musculoskeletal Disease” in which this paper was published is a prestigious academic journal in the field of musculoskeletal medicine, with a 5-Year Impact Factor of 4.774 as of 2022.